SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention (Beijing CDC) to supply seasonal influenza vaccine to the citizens of Beijing. Dr. Weidong Yin, Chairman, President] [Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility Sinovac Biotech Ltd. (SVA), a leading China-based vaccine manufacturer, announced today that it has received GMP certification from the China State Food and Drug Administration (SFDA) for the Company's dedicated mumps vaccine production plant at its Sinovac Dalian facility. The SFDA issued a public announcement on September 12, 2012, stating] [Sinovac Awarded Tenders in Beijing and Shanghai to Supply Inactivated Hepatitis A Vaccine Healive® Under Expanded Immunization Program SVA BEIJING, Sept. 25, 2012 -- Sinovac Biotech Ltd. ( Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "We are pleased to have been selected as the sole supplier of the inactivated hepatitis A vaccine in prefilled syringe in both] []

By | 2016-03-24T00:58:41+00:00 September 26th, 2012|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Receives Beijing CDC Tender Award to Supply

[Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention (Beijing CDC) to supply seasonal influenza vaccine to the citizens of Beijing. Dr. Weidong Yin, Chairman, President] [Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility Sinovac Biotech Ltd. (SVA), a leading China-based vaccine manufacturer, announced today that it has received GMP certification from the China State Food and Drug Administration (SFDA) for the Company's dedicated mumps vaccine production plant at its Sinovac Dalian facility. The SFDA issued a public announcement on September 12, 2012, stating] [Sinovac Awarded Tenders in Beijing and Shanghai to Supply Inactivated Hepatitis A Vaccine Healive® Under Expanded Immunization Program SVA BEIJING, Sept. 25, 2012 -- Sinovac Biotech Ltd. ( Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "We are pleased to have been selected as the sole supplier of the inactivated hepatitis A vaccine in prefilled syringe in both] []

By | 2016-03-24T00:59:35+00:00 September 26th, 2012|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Holds 2012 Annual General Meeting of Shareholders BEIJING, Aug. 23, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that it held its 2012 Annual General Meeting of Shareholders on Wednesday, August 22, 2012 at 9:00 a.m. Beijing Time. The required quorum, a majority of the common shares outstanding, was voted] []

By | 2016-03-24T01:00:38+00:00 September 26th, 2012|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Holds 2012 Annual General Meeting of Shareholders

[Sinovac Holds 2012 Annual General Meeting of Shareholders BEIJING, Aug. 23, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that it held its 2012 Annual General Meeting of Shareholders on Wednesday, August 22, 2012 at 9:00 a.m. Beijing Time. The required quorum, a majority of the common shares outstanding, was voted] []

By | 2016-03-24T01:01:43+00:00 September 26th, 2012|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

DHRM [Dehaier Medical Systems] 8-K: (Original Filing)

[Dehaier Medical Wins Three Year Procurement Agreement from Major Ukrainian Medical Equipment Manufacturer DHRM BEIJING, Sept. 21, 2012 /PRNewswire-FirstCall/ — Dehaier Medical Systems Ltd. (NASDAQ: During the three-year term of the agreement, the purchaser will procure Dehaier's proprietary air compressors, customized trolleys and accessories, which will be used in hospital intensive care units, emergency rooms, operation rooms, respiratory departments and] [FORM 8-K CURRENT REPORT Date of report (date of earliest event reported): September 21, 2012 DEHAIER MEDICAL SYSTEMS LIMITED British Virgin Islands 001-34661 Not Applicable (State or Other Jurisdiction of Incorporation) (IRS Employer Identification No.) Suite 501, Jiuzhou Plaza 83 Fuxing Road, Haidian District Beijing 100856 China +86 (10) 5166-0080 Not Applicable (Former name or former address, if changed since]

DHRM [Dehaier Medical Systems] 8-K: Dehaier Medical Wins Three Year Procurement Agreement from

[Dehaier Medical Wins Three Year Procurement Agreement from Major Ukrainian Medical Equipment Manufacturer DHRM BEIJING, Sept. 21, 2012 /PRNewswire-FirstCall/ — Dehaier Medical Systems Ltd. (NASDAQ: During the three-year term of the agreement, the purchaser will procure Dehaier's proprietary air compressors, customized trolleys and accessories, which will be used in hospital intensive care units, emergency rooms, operation rooms, respiratory departments and] [FORM 8-K CURRENT REPORT Date of report (date of earliest event reported): September 21, 2012 DEHAIER MEDICAL SYSTEMS LIMITED British Virgin Islands 001-34661 Not Applicable (State or Other Jurisdiction of Incorporation) (IRS Employer Identification No.) Suite 501, Jiuzhou Plaza 83 Fuxing Road, Haidian District Beijing 100856 China +86 (10) 5166-0080 Not Applicable (Former name or former address, if changed since]

AUO [AU OPTRONICS] 20-F/A: (Original Filing)

[Page EXPLANATORY NOTE i PART I 2 ITEM 5 OPERATING AND FINANCIAL REVIEW AND PROSPECTS 2 5.A. Operating Results 2 5.B. Liquidity and Capital Resources 14 5.C. Research and Development 18 5.D. Trend Information 19 5.E. Off-Balance Sheet Arrangements 19 5.F. 19 PART III 21 ITEM 18 FINANCIAL STATEMENTS 21 ITEM 19 21 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS 23 i] [Certification I, Shuang-Lang (Paul) Peng, certify that: 1. I have reviewed this annual report on Form 20-F/A of AU Optronics Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification I, Andy Yang, certify that: 1. I have reviewed this annual report on Form 20-F/A of AU Optronics Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [906 Certification 100 F Street, N.E. Ladies and Gentlemen: Shuang-Lang (Paul) Peng, the President of AU Optronics Corp., certifies that, to the best of his knowledge: 1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and 2. the information contained in the Report fairly presents, in all material respects, the financial condition] [906 Certification 100 F Street, N.E. Ladies and Gentlemen: Andy Yang, the Chief Financial Officer of AU Optronics Corp., certifies that, to the best of his knowledge: 1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and 2. the information contained in the Report fairly presents, in all material respects, the financial]

By | 2016-03-25T21:34:40+00:00 September 26th, 2012|Categories: AUO, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

AUO [AU OPTRONICS] 20-F/A: Page EXPLANATORY NOTE i PART I 2 ITEM

[Page EXPLANATORY NOTE i PART I 2 ITEM 5 OPERATING AND FINANCIAL REVIEW AND PROSPECTS 2 5.A. Operating Results 2 5.B. Liquidity and Capital Resources 14 5.C. Research and Development 18 5.D. Trend Information 19 5.E. Off-Balance Sheet Arrangements 19 5.F. 19 PART III 21 ITEM 18 FINANCIAL STATEMENTS 21 ITEM 19 21 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS 23 i] [Certification I, Shuang-Lang (Paul) Peng, certify that: 1. I have reviewed this annual report on Form 20-F/A of AU Optronics Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification I, Andy Yang, certify that: 1. I have reviewed this annual report on Form 20-F/A of AU Optronics Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [906 Certification 100 F Street, N.E. Ladies and Gentlemen: Shuang-Lang (Paul) Peng, the President of AU Optronics Corp., certifies that, to the best of his knowledge: 1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and 2. the information contained in the Report fairly presents, in all material respects, the financial condition] [906 Certification 100 F Street, N.E. Ladies and Gentlemen: Andy Yang, the Chief Financial Officer of AU Optronics Corp., certifies that, to the best of his knowledge: 1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and 2. the information contained in the Report fairly presents, in all material respects, the financial]

By | 2016-03-25T21:35:34+00:00 September 26th, 2012|Categories: AUO, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar